Carol Giltner Gallagher - 22 Jun 2023 Form 4 Insider Report for Mirati Therapeutics, Inc.

Role
Director
Signature
/s/ John Moriarty, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
22 Jun 2023
Net transactions value
$0
Form type
4
Filing time
23 Jun 2023, 17:18:02 UTC
Previous filing
12 Jun 2023
Next filing
15 Nov 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRTX Common Stock Award $0 +7,555 $0.000000 7,555 22 Jun 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRTX Employee Stock Option (Right to Buy) Award $0 +12,784 $0.000000 12,784 22 Jun 2023 Common Stock 12,784 $38.02 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This represents a Restricted Stock Unit grant with a vesting period of 3 years that vests 33% annually from grant date.
F2 The shares subject to the Option shall vest and become exercisable in 36 equal monthly installments following the date of grant.